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Summary
We have identified and characterized a genomic sequence
with some features typical of Alu-like mobile elements
rearranged into the dystrophin gene in a family affected
by X-linked dilated cardiomyopathy. The Alu-like se-
quence rearrangement occurred 2.4 kb downstream
from the 5′ end of intron 11 of the dystrophin gene. This
rearrangement activated one cryptic splice site in intron
11 and produced an alternative transcript containing the
Alu-like sequence and part of the adjacent intron 11,
spliced between exons 11 and 12. Translation of this
alternative transcript is truncated because of the nu-
merous stop codons present in every frame of the Alu-
like sequence. Only the mutant mRNA was detected in
the heart muscle, but in the skeletal muscle it coexisted
with the normal one. This result is supported by the
immunocytochemical findings, which failed to detect
dystrophin in the patient’s cardiac muscle but showed
expression of a reduced level of protein in the skeletal
muscle. Comparative analysis of the Alu-like sequence
showed high homology with other repeated-ele-
ment–containing regions and with several expressed se-
quence tags.We suggest that thisAlu-like sequence could
represent a novel class of repetitive elements, reiterated
and clustered with some known mobile elements and
capable of transposition. Our report underlines the com-
plexity of the pathogenic mechanism leading to X-linked
dilated cardiomyopathy but suggests that differences in
tissue-specific expression of dystrophin mutations may
be a common feature in this condition.
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Introduction
The cardiomyopathies represent a major cause of car-
diovascular morbidity and mortality, and, within this
group, dilated cardiomyopathy (DC) is the most com-
mon of the various forms (Manolio et al. 1992). DC can
result from numerous causes, but increasing interest in
the genetic predisposition to this condition recently has
developed. Although several disease loci responsible for
the dominant forms of DC have been mapped (Durand
et al. 1995; Krajinovic et al. 1995; Olson and Keating
1996; van der Kooi et al. 1997), the only gene known
to be responsible for one form of DC is the dystrophin
gene located on the X chromosome (MIM 310200).Mu-
tations in this gene are usually associated either with the
severe Duchenne-type muscular dystrophy (DMD) or
with its milder allelic variant, Beckermuscular dystrophy
(BMD) (for review, see Ahn and Kunkel 1993), in which
the heart also is affected. In rare instances, however,
dystrophin mutations have been associated with X-
linked DC (XLDC) in the absence of muscle weakness
(Muntoni et al. 1993; Towbin et al. 1993; Yoshida et
al. 1993; Milasin et al. 1996). The only suggestion of
skeletal-muscle involvement in these families was the
presence of either raised serum creatine kinase (CK) lev-
els (Muntoni et al. 1993; Towbin et al. 1993; Yoshida
et al. 1993) or occasional myalgias after strenuous phys-
ical exercise (Milasin et al. 1996).
Interspersed repetitive DNA elements (IRS) represent
different classes of DNA sequences, with high, medium,
and low grades of reiteration in the eukaryote genome
(Weiner et al. 1986; Deininger et al. 1992; McNaughton
et al. 1995). Three major types of IRS have been iden-
tified—the long interspersed nucleotide elements (LINEs;
∼6 kb long), the short interspersed nucleotide elements
(SINEs; ∼300 bp), and the transposon-like human ele-
ments (THE; 2.5–7 kb). These three classes of IRS, to-
gether with many other, less abundant, repetitive ele-
ments, have provided an important contribution to
genome evolution (Makalowski et al. 1994). These el-
ements, also called “mobile elements,” possess the ca-
pability to change their genomic location by transposi-
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Figure 1 Pedigree of family with XLDC. The blackened squares denote affected patients; and the circles including black dots denote
obligate female carriers. A horizontal tic mark above a symbol indicates that the individual was analyzed; and an asterisk indicates that the
individual is a carrier of the dystrophin rearrangement.
tion. This represents an incompletely understood event
by which a master repetitive element, representing the
ancestor consensus sequence from which the different
IRS families have originated, moves its genomic locali-
zation via an RNA intermediate and reverse transcrip-
tion (Mathias et al. 1991; Craig 1995). Among the SI-
NEs, the Alu family constitutes the major interspersed
repeat of primate genomes, with 1500,000 copies in the
human haploid genome (Britten et al. 1988).
Alu elements and LINEs occasionally have been as-
sociated with genetic diseases, mainly by providing the
sites for homologous recombination, because of their
high homology to master elements. These recombina-
tions result in deletions or other, more-complex genomic
rearrangements (Muratani et al. 1991; Wallace et al.
1991; Li and Bray 1993; Vidaud et al. 1993; Janicic et
al. 1995). Insertions of IRS into human genes via ret-
roposition also have been hypothesized but, both in the
human and in other species, have been demonstrated
only in a few cases (Homes et al. 1994; Kingsmore et
al. 1994). Another rare mutation mechanism can be a
point mutation that activates both a cryptic splice site
and the splicing of intronic Alu elements into the mature
transcript (Mitchell et al. 1991; Knebelmann et al.
1994).
In this report we present evidence for a mutation in
the dystrophin gene in a family with XLDC due to a
rearrangement of an Alu-like element within intron 11.
This event modified the splicing in a tissue-specific man-
ner, resulting in absence of dystrophin expression only
in the heart muscle. Comparative sequence analysis sug-
gests that this Alu-like sequence is part of a novel, tran-
scriptionally active repetitive-element family, given the
absence of significant homology with Alu, LINEs, and
other known IRS consensus sequences.
Subjects and Methods
Clinical Studies
This previously unreported Italian family is of Sar-
dinian descent. Diagnosis of DC was established on the
basis of clinical history, physical examination, chest ra-
diography, electrocardiography (EKG), echocardio-
graphy, and cardiac catheterization. The diagnostic cri-
teria for DC were those promulgated by the World
Health Organization (Richardson et al. 1996). The pro-
band (individual III-12; fig. 1) is a 20-year-old male who
was well and physically very active until the age of 16
years, when he was admitted after contracting viral hep-
atitis. Radiography of the chest showed an unexpected
moderate cardiomegaly, and high serum CK levels were
documented (1,970 IU/liter [normal !195 IU/liter]).
EKG showed sinus tachycardia, left-atrial enlargement,
and right-bundle-branch block. The left-ventricular ejec-
tion fraction (EF) was reduced (17%), as assessed by
echocardiography. At that time the patient was virtually
asymptomatic, and a diagnosis of DC was made. One
year later the patient was admitted for an episode of
acute congestive heart failure, and echocardiography
confirmed both the severe dilatation of the right and left
ventricles and a reduction of the EF. A right-ventricular
endomyocardial biopsy and a skeletal-muscle biopsy
were performed, for diagnostic purposes, after informed
consent was obtained. Since then, the patient has been
in a stable clinical condition and complains only of dysp-
nea, after strenuous exercise. The results of a neurolog-
ical examination in 1996 were unremarkable; in partic-
ular, the patient had normal muscle strength and did not
have muscle wasting or hypertrophy. Several other fam-
ily members were affected by DC, and analysis of the
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Table 1
Primer Sequences Used
Primer Sequence (5′–3′) Orientation
Annealing
Temperature
(C)
Ex11F GAAGTAAGCTGATTGGAAC Forward 61
Ex12R GTTGTTGTACTTGGCGTTTTA Reverse 61
Int11F GATGTTCAGTAATAAGTTGCTTT Forward 60
Int11R AGCTTCCAAAACTTGTTAGTC Reverse 60
SeqF ACAGGGTTTGGATAGATCCAGTC Forward 60
SeqR GACTGGATCTATCCAAACCCTGT Reverse 60
Dysint GTTACTTCAGATGATGACTCATTG Reverse 61
Trasp1A CAAACCTTTTCTACAAGAAATGGT Forward 62
Trasp1B ACCATTTCTTGTAGAAAAGGTTTG Reverse 62
Dysgen GTTCAGTTTCCATTATCATGGTC Forward 63
pedigree suggested an X-linked inheritance (fig. 1). Spe-
cifically, the 29-year-old older brother (individual III-10;
fig. 1) also was found to have elevated CK levels. The
results of physical examination of this individual were
unremarkable, whereas EKG showed ventricular hyper-
trophy. Echocardiography disclosed a left-ventricular
dilatation, reduced (40%) left-ventricular EF, and mild
mitral-valve incompetence. The individual is virtually
asymptomatic. A maternal cousin (individual III-1) died
at the age of 18 years because of heart failure. In addition
to the cardiac involvement, he also had muscle weakness
suggesting a BMD phenotype. Individuals III-7, III-8, III-
9, and III-11 are clinically normal and have normal se-
rum CK levels.
Cardiac-muscle and skeletal-muscle biopsy specimens
from the proband (individual III-12; fig. 1) were avail-
able for immunocytochemical and transcription studies.
Peripheral blood was collected from six members of the
family (individuals III-7–III-12; fig. 1).
Immunocytochemical Study
Skeletal-muscle and cardiac-muscle biopsy specimens
were studied according to standard techniques, including
immunocytochemistry (Sewry et al. 1993). Six-micron
unfixed cryostat sections were immunostained with a
panel of anti-dystrophin antibodies (Novocastra).
Molecular Analysis
Transcription studies.—Total RNA was isolated from
skeletal-muscle and cardiac-muscle biopsy specimens by
the method of Chomczynsky and Sacchi (1987). Re-
verse-transcription–PCR for cDNA synthesis was per-
formed with random hexanucleotide primers and the
Moloney murine leukemia virus reverse transcriptase
(Pharmacia), according to a procedure that has been
described elsewhere (Muntoni et al. 1995).
The amplification products were electrophoresed on
a high-resolution agarose gel (Electran; Sigma) and were
visualized after being stained with ethidium bromide.
The amplification products were purified on Glass Max
columns (Gibco), if necessary. The PCR reactions (Ther-
mal Cycle model 480; Perkin-Elmer) were performed by
use of Taq Pfu Polymerase (Stratagene); the amplification
conditions are available on request.
Genomic studies.—Genomic DNA was isolated from
peripheral blood obtained from individuals III-7–III-12
(fig. 1), by standard methods (Kunkel et al. 1983). Mul-
tiplex DNA amplifications to exclude the common de-
letions of dystrophin exons were performed (courtesy of
Prof. M. A. Melis), according to the methods of Cham-
berlain et al. (1988) and Beggs et al. (1990).
The pairs of oligonucleotides Ex11F/Int11R and
Int11F/Ex12R (table 1) were designed for amplification
and sequencing of the exon-intron boundaries of intron
11, according to the published sequences (accession
number I07692.gbpat; Monaco et al. 1988). Several
oligonucleotides also were designed to amplify the ge-
nomic region including the 5′ end of intron 11 in controls
and patients. The sequences of all oligonucleotides used
are shown in table 1; the conditions of amplification are
available on request. For PCR, Perkin-Elmer DNA
Thermo Cycler 480 and Perkin-Elmer 2400 were used.
Taq Plus polymerase (Stratagene) and Taq Expand Sys-
tem (Boehringer) were used for the amplification reac-
tions, with the appropriate incubation buffers. Am-
plification products were gel purified, when necessary,
by agarase digestion (Boehringer).
To isolate the upstream region of intron 11 in indi-
vidual III-12, we adopted a PCR-walking method ena-
bling us to amplify and sequence the 5′ 2.5-kb intronic
region (Ferlini and Muntoni 1998). Several attempts, by
means of Long Taq polymerases approaches (Taq Ex-
pand System and Takara LA polymerase), to amplify the
genomic fragment downstream from the Alu-like se-
quence rearrangement failed, probably because of the
large size of intron 11.
After digestion of genomic DNA from patients and
controls, Southern blot analysis was performed with
BglII, HindIII, XmnI, EcoRI, and TaqI restriction en-
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zymes, and the products were transferred onto Gene
Screen Plus (NEN) in 10# SSC buffer. Membranes were
hybridized by a-[32P] (dATP)–radiolabeled probes (Me-
gaprime and Nick Translation kits; Amersham) by the
Church and Gilbert (1984) method, under highly com-
petitive conditions ( 300 mg herring-sperm DNA). The
probes used were the 2b-3 dystrophin cDNA fragment
(a gift from Dr. R. Roberts), the 159-bp sequence in-
serted into individual III-12’s RNA (probe Past), and a
2.5-kb intron 11 amplification product (probe 2.5 KM)
obtained from individual III-12. For the Past and 2.5
KM probes, very-high-stringency conditions (hybridi-
zation at 68C and washing at 70C) were used. Mem-
branes were exposed for 1–5 days at 80C, for
autoradiography.
Cloning and sequencing.—For cloning procedures,
the cDNA-amplification products were cloned in the
pGEM vector (TA cloning system; Promega) and were
sequenced manually (Sequenase kit, version 2.0; Phar-
macia). Genomic DNA fragments were cloned into PCR
Script SK AMP Vector (Stratagene), and this was
followed by either manual (Sequenase kit, version 2.0;
Pharmacia) or automated (Applied Biosystems) se-
quencing.
Comparative sequence analysis.—Comparative se-
quence analysis was done by means of the GCG Wis-
consin Package, with FASTA and BLAST.
Results
Skeletal-Muscle and Cardiac-Muscle Biopsies
Histological analysis of the skeletal-muscle biopsy
specimen from individual III-12 (see the pedigree in fig.
1) showed a mild myopathic picture, with mild varia-
bility in fiber size, an increased number of internal nuclei,
a few areas of degeneration/regeneration, and no fibrosis
(fig. 2e). In contrast, a severe dystrophic cardiomyopa-
thy, characterized by marked fibrosis and variability in
fiber size, was present in the cardiac-muscle biopsy spec-
imen (fig. 2f).
Immunocytochemical analysis of individual III-12’s
skeletal-muscle biopsy specimen showed a moderate re-
duction in staining when a panel of anti-dystrophin an-
tibodies was used (fig. 2b). The cardiac muscle, on the
contrary, showed a total absence of staining (fig. 2d).
These results indicated the presence of a dystrophino-
pathy that affected the cardiacmusclemore severely than
it affected the skeletal muscle.
Transcription Studies
Transcription analysis of total skeletal-muscle RNA
of the proband, III-12, performed with Ex11F and
Ex12R used as primers to amplify exons 11 and 12,
showed a higher-molecular-weight fragment, in addition
to that having the expected size (fig. 3a). In contrast,
this larger product was virtually the only one present in
the cardiac-muscle biopsy specimen from the propositus,
and it was not observed in five skeletal-muscle and three
cardiac-muscle tissues from controls (fig. 3a). Sequence
analysis of these two fragments demonstrated that the
smaller-size product represented the normal gene tran-
script, whereas the other fragment contained an inserted
sequence of 159 bp. A schematic representation of the
alternative dystrophin transcript is shown in figure 3b.
The 159-bp sequence inserted into the patient’s
mRNA caused a nontranslated message, since analysis
of its sequence showed 12 stop codons (one every 13
bp), which were present in all three reading frames and
were responsible for a premature stop of the message,
despite the conservation of the canonical frame of the
dystrophin message. Furthermore, the sequence con-
tained 39% GC and 61% AT, indicating that this is
an AT-rich region. These characteristics, together with
genomic data and comparative analysis (see below), are
suggestive of an Alu-like element spliced into the tran-
script and causing a prematurely truncated dystrophin.
The finding that the cardiac muscle expressed only the
truncated transcript whereas, in the skeletal-muscle
RNA, the latter was coexpressed with the normal tran-
script is in keeping with both the immunocytochemical
and clinical findings in this family, in which no signifi-
cant muscle weakness was present.
Genomic Studies
PCR and sequence analysis.—No genomic deletion of
the dystrophin gene was found after combinedmultiplex
PCR analysis (data not shown). Sequence analysis of the
canonical donor and acceptor splicing sites of intron 11
in the propositus, individual III-12, excluded a mutation
in both these regions, including the flanking splicing con-
sensus sequences (data not shown).
A pair of primers located within the transcribed Alu-
like sequence—namely, SeqF and Dysint (table 1 and fig.
3c)—were designed and used to amplify both skeletal-
muscle and cardiac-muscle cDNAs and genomic DNA
from patients and relatives (fig. 4a). This confirmed that
the same Alu-like fragment spliced into the patient’s
RNA was present in the genomic DNA of the two af-
fected brothers (III-10 and III-12) and in that of two of
the three sisters (III-8 and III-11) but not in that of the
unaffected brother (III-7). Similarly, when both the same
reverse primer (Dysint) and a forward primer (Dysgen)
located in the intronic region flanking, upstream, the
Alu-like sequence (fig. 3d) were used, an amplified frag-
ment present only in the patients and not in 30 female
controls was found (fig. 4b). Further amplification, using
the same forward primer and a different reverse primer
(Trasp1B), located in the middle of theAlu-like sequence
(fig. 3c), gave identical results (fig. 4c), indicating the
presence of a rearrangement in this intronic region.
Figure 2 a–d, Immunocytochemical analysis of skeletal-muscle and cardiac-muscle biopsy specimens from a control and individual III-
12, by means of Dys3, an N-terminal anti-dystrophin antibody. Expression of dystrophin is normal in skeletal muscle and cardiac muscle of
the control (a and c). In individual III-12’s skeletal-muscle DNA (b), there is a reduction in staining, compared with that in the control, whereas,
in his cardiac-muscle (d), dystrophin is absent. e and f, Section of skeletal-muscle biopsy specimen (e) and cardiac-muscle biopsy specimen (f),
stained with hematoxylin and eosin (scale bar  100 mm). The specimens show myopathic changes in the skeletal muscle and fibrosis and
cardiomyocyte hypotrophy in the cardiac muscle.
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Figure 3 a, Transcription analysis of skeletal-muscle RNA (lane A) and cardiac-muscle RNA (lane B) of individual III-12, performed with
Ex11F and Ex12R used as oligonucleotides. A 257-bp, larger fragment is visible, in addition to the 99-bp fragment expected. The alternative
transcript represented the only transcript in the cardiac muscle of the patient and is not present in skeletal-muscle RNA (lanes C and D) or
cardiac-muscle RNA (lane E) of a control. Lane M, Marker IX (Boehringer). The smaller bands (!50 bp) represent primer dimers. b, Schematic
representation of both the alternative and the normal dystrophin transcripts. The unblackened squares denote the normal exons 11 and 12;
and the blackened squares and the patterned squares denote the intronic region and theAlu-like sequence, respectively. c, Schematic representation
of the mRNA configuration in individual III-12. The rightward- and leftward-facing arrows indicate, respectively, the forward and reverse
primers used for cDNA and genomic-DNA amplification; the blackened bar denotes the normal intron 11 region (23 bp), spliced in the transcript;
and the patterned bar denotes the Alu-like sequence (136 bp). d, Schematic representation of the dystrophin gene intron 11 in individual III-
12. The rightward- and leftward-facing arrows indicate, respectively, the forward and reverse primers used for genomic-DNA amplification;
the unblackened squares indicate exon 11 and 12 of the dystrophin gene; the blackened bar denotes the normal intron 11 region; the patterned
bar denotes the Alu-like sequence; and the diagonally striped bar denotes the intron 11 region whose sequence is still unknown; and the
unblackened downward-facing arrow indicates the cryptic splicing site normally present in intron 11. The two genomic probes (2.5 KM and
Past) used for Southern blot analysis are shown below the diagram.
However, amplification under very-low-stringency
conditions (58C) of the 3′ region of the Alu-like se-
quence (fig. 3c), with the forward primer Trasp1A and
the reverse primer Dysint, resulted in an amplification
in all family members and in controls, including a child
with both DMD and a genomic deletion encompassing
intron 11 (data not shown). This finding suggests that
this sequence is present in at least one copy in the human
genome.
All these data suggest that a rearrangement of a novel
Alu-like sequence in intron 11 of the dystrophin gene
occurred in the family that we studied, segregating with
the disease. We can hypothesize that this rearrangement
also was present in individual III-1, who also suffered
with muscle weakness and DC; and, if this is the case,
we can speculate that this rearrangement in intron 11
could have occurred in the maternal grandmother (I-2;
fig. 1), representing an obligate carrier. A schematic rep-
resentation of the genomic structure of this region in our
patients, as well as the location of the primers and the
probes used, is shown in figure 3d.
To determine the site of the Alu-like rearrangement in
intron 11, we used a forward primer located in exon 11
(Ex11F) and a reverse primer located in the 3′ end of
the sequence (Dysint). We amplified a 2,552-bp fragment
from patients’ genomic DNA but not from that of six
male controls (fig. 4d). To refine the position in which
theAlu-like insertion occurred in intron 11, we amplified
and sequenced this fragment by PCR walking, using var-
ious sets of primers (Ferlini and Muntoni 1998), and
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Figure 4 Amplification of the intron 11 region containing the Alu-like rearrangement. a, Amplification, by primers SeqF and Dysint, of
genomic DNA from individual III-10 (lane A), individual III-12 (lane B), female III-9 (lane C), and female III-11 (lane D), and skeletal-muscle
and cardiac-muscle cDNAs from individual III-12 (lanes E and F, respectively). A 137-bp fragment was amplified from all samples, with the
exception of that from individual III-9 (a noncarrier sister of the propositus). Lane X, Molecular-weight marker V (Boehringer). b,Amplification,
by primers Dysgen (located in the intronic region flanking upstream the Alu-like sequence) and Dysint, of genomic DNA from affected males
III-10 and III-12 (lanes A and B, respectively), one noncarrier and one carrier sister (individuals III-9 [lane C] and III-11 [lane D], respectively),
one healthy brother (individual III-7 [lane E]), and healthy controls (lanes F–J). The 301-bp fragment is present only in the patients and in a
carrier sister and not in the healthy brother, the noncarrier sister, or controls. Lane M,Molecular-weight marker VI (Boehringer ). c,Amplification
of genomic DNA from the same individuals as are represented in b, by the same forward primer (Dysgen) but with a different reverse primer
(Trasp1B). The pattern of amplification (236 bp) is identical to that obtained with the primer combination described in b, excluding the possibility
that the amplification obtained in this family is due to a point mutation occurring in the region covered by the Dysint primer. LaneM,Molecular-
weight marker VI (Boehringer). d, Amplification, by primers Ex11F and Dysint, of genomic DNA from the two affected brothers, III-10 and
III-12 (lanes A and B, respectively), and from two controls (lanes C and D). A fragment that is ∼2.5 kb is present only in the patients. Lanes
K and M, Molecular-weight markers X and VI, respectively (Boehringer ).
identified a minimal region of 22 bp, at nucleotide po-
sitions 2349–2371 of intron 11, normally present in pa-
tients and controls (data not shown).
In conclusion, we were able to establish that the 2.5-
kb fragment contains both the 5′ 2,371-bp of intron 11
and a 136-bp Alu-like sequence in which a rearrange-
ment occurred. Interestingly, the 3′ end of the novel in-
tron 11 sequence, which is flanking, upstream, the Alu-
like sequence, contains a conserved AG acceptor splicing
site with a flanking pyrimidine-rich consensus sequence,
preferentially utilized in the patient’s cardiac muscle.
Southern blot analysis.—Hybridization of BglII and
HindIII Southern blots, using the cDNA 2b-3 as a probe
encompassing exon 11 and 12 of the dystrophin gene,
failed to show any gross rearrangements in patients’
DNA. On the other hand, sequence analysis of the 5′
end of intron 11 showed both HindIII and BglII restric-
tion sites in the region upstream from the rearrangement,
providing an explanation for the normal pattern found
in patients. Hybridization of BglII-, HindIII-, XmnI-,
TaqI-, and EcoRI-digested Southern blots, using the
probe Past (the 159-bp PCR fragment; fig. 3d), gave
hybridization patterns similar to that obtained with a
multicopy-probe hybridization (data not shown). Hy-
bridization with the XmnI digestion’s membrane, by use
of the 2.5-kb PCR fragment (probe 2.5 KM) including
both the 5′ end of intron 11 and the Alu-like sequence
(probe Past) (fig. 3d) under high-stringency conditions
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Figure 5 Southern-blot hybridization using both the 2.5 KM
fragment as a probe andXmnI restriction enzyme. Lanes A–C, Normal
DNA from controls. Lanes D and E, DNA of the affected brothers,
III-10 and III-12. Lane F, DNA from female III-9. Lane G, DNA from
female III-11. In addition to the normal fragment, an abnormal frag-
ment that is ∼10 kb is present only in the two affected males and the
carrier sister, III-11.
(68C–72C), showed the presence of a unique fragment
(∼10 kb) in the two affected brothers as well as in one
sister, who also carried the normal-size allele (fig. 5). The
pattern of segregation of the XmnI fragment was iden-
tical to that found in the genomic amplifications men-
tioned above, indicating that the two brothers and two
sisters (individuals III-10 and III-12 and individuals III-
8 and III-11, respectively; see fig. 1) are carrying the
same genomic rearrangement, whereas the healthy
brother (III-7) and the other sister (III-9) are not. Because
of the large size (130 kb, as reported in the Leiden Mus-
cular Dystrophy Pages) of the 3′ of intron 11, we have
not been able to ascertain whether the donor splice site
has been created by the genomic rearrangement or is
endogenously present in intron 11; nor have we been
able to ascertain the 3′ end of the rearrangement. We
cannot exclude the possibility that the Alu-like sequence
has been inserted by retrotransposition in intron 11. We
have, however, established that a normally present ac-
ceptor splicing site in intron 11 of the dystrophin gene
was activated by a rearrangement consisting of x100
bp and involving an Alu-like sequence.
Comparative sequence analysis.—We have submitted
both the wild-type 5′ end of intron 11, nucleotide po-
sitions 1–2371 (accession number Y13187), and the re-
arranged 136-bp Alu-like sequence (accession number
Y13186) to the DDBJ/EMBL/GenBank nucleotide-se-
quence databases.
Comparative analysis of theAlu-like inserted sequence
failed to detect any significant homology either with the
Alu and LINE1 consensus, with other known repetitive-
element families, or with THE1; instead, the analysis
showed a significant homology (180%, on a minimum
overlap of 100 bp) with several human genomic se-
quences. These included (a) a series of cosmids mapped
on X chromosome—in Xq28 (accession number
Z47066), in Xq21-q22 (accession numbers Z68332,
Z70050, Z70758, Z73967, Z80900, Z69367, Z75894,
Z68871, Z68328, Z70689, Z69838, Z74477, Z68871,
Z70226, Z68289, Z73497, Z75745, and Z70233), in
Xq23 (accession numbers AC000055 and AC000114),
in Xq22 (in the expressed sequence tags [ESTs] of glyc-
erol kinase pseudogene [accession number Z73986]),
and in Xp22 (accession number U70984); (b) a region
flanking the 3′ UTR of the FRAXA gene on Xq28 and
containing severalAlu elements and LINE1s; (c) cosmids
Z49862, Z49235, and Z68165, flanking theHuntington
gene on chromosome 4p16.3; and (d) other cosmids,
located in 7q21-q22 (accession numbers AC000066,
AC000121, AC000119, and AC000057) and including
the BRCA2 gene region on 13q12-q13 (accession num-
ber Z73360). The homologous region that our Alu-like
sequence shared with these sequences always occurred
within nucleotide positions 25–136 or 25–79. Interest-
ingly, this was a region in which a significant (80%)
homology with two eukaryotic promoters was found
(accession numbers EPD14029 and EPD17097). In ad-
dition, comparative analysis with the EMBL-EST bank
revealed homology with 13 ESTs, the most relevant
(80%) being two Homo sapiens cDNA sequences (ac-
cession numbers C02353 and Z25899). All these ESTs
represent truncated messages and do not have an open
reading frame.
Comparative analysis of the 5′ region of intron 11 of
the dystrophin gene indicated a significant (70%) ho-
mology with several cosmids mapped at Xq22 and 7q22,
as well as withHomo sapiens ESTs (Ferlini andMuntoni
1998). In this case, again, the cosmids contained several
Alu elements and LINE1s.
Discussion
In this report we have described a family affected by
XLDC with an unusual dystrophin gene mutation. The
disease mechanism in this family was an intronic rear-
rangement inducing the inclusion of an Alu-like se-
quence and part of the 5′ adjacent intronic region in the
dystrophin mRNA. This sequence contained several stop
codons, causing a prematurely truncated message. In
skeletal muscle, the normal transcript coexisted with the
alternative message, allowing the production of suffi-
cient dystrophin to account for the lack of significant
muscle damage and weakness. On the other hand, the
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alternative transcript represented virtually the only mes-
sage in the cardiac muscle and is likely to be responsible
for the isolated cardiomyopathic phenotype.
The genomic mutation in this family consisted of a
small rearrangement located 2.4 kb downstream from
the 5′ end of intron 11 of the dystrophin gene. Both
transcription and genomic data suggest that the Alu-
like–sequence insertion is responsible for the XLDC in
our patients. The fact that the mRNA insertion intro-
duced different stop codons in the canonical reading
frame demonstrates that the spliced sequence does not
represent a common alternative spliced form of the dys-
trophin gene, as is also evident from the analysis of sev-
eral samples of skeletal-muscle and cardiac-muscle
RNAs from controls. Moreover, the genomic segregation
of the rearranged sequence with the XLDC in the mem-
bers of this family whom we analyzed confirms the link-
age between this mutation and the disease. Amplification
of DNA from several controls (180 chromosomes) failed
to show this genomic configuration, confirming that it
does not represent a common DNA polymorphism.
This rearrangement contained a sequence with simi-
larities both to SINE sequences, including Alu, and to
LINE1 (AT content, multiple stop codons’ contents, ho-
mology with EST sequences, and reiterated presence, in
both strand orientations, in the human genome). Fur-
thermore, low-stringency-condition amplification, as
well as Southern analysis, gave a multicopy sequence
pattern.
The comparative data analysis suggested that thisAlu-
like sequence represents a novel expressed multicopy ge-
nomic element. This hypothesis is supported by the fact
that this sequence is (a) present in multiple copies in the
human genome; (b) homologous to other sequences in
the data bank, in a way that is suggestive of a family of
interspersed repeats; and (c) homologous to several hu-
man ESTs, all of them without an open reading frame.
This strongly suggests that these ESTs represent RNA
intermediates, originating from related genomic se-
quences, transcriptionally active, and potentially capable
of retrotransposition. In addition, the genomic regions
with homology to our sequence are rich in Alu elements,
THEs, LINE1s, and other repetitive elements, which
normally are clustered as a well-recognized feature of
IRS (Britten 1996; Weiner et al. 1986).
Both the evidence of a rearrangement in this family
and the features of this novel repetitive sequence suggest
that the latter might be part of a mobile element. This
element could have been rearranged into intron 11 be-
cause of a nonhomologous recombination, facilitated by
the presence of the repeats in this region, or it could
have been retrotransposed and inserted via an RNA in-
termediate. This latter possibility also seems to be sup-
ported by the fact that the genomic as well as the EST
regions, described above and sharing homology with the
Alu-like sequence, have both strand orientations. Ad-
ditional evidence supporting the hypothesis that this se-
quence meets the basic requirements of IRS (Britten
1996) derives from the observation that homology with
other known repetitive elements is present in intron 11
of the dystrophin gene.
Alu or LINE1 insertion rearrangements have been re-
ported to be associated with human diseases only in very
rare instances (Muratani et al. 1991;Wallace et al. 1991;
Li and Bray 1993; Vidaud et al. 1993; Janicic et al.
1995). Alu, THE, and LINE1 also have been identified
in dystrophin introns and, rarely, are associated with
gross mutations leading to DMD or BMD (Pizzuti et al.
1992; Narita et al. 1993; Homes et al. 1994). In an
earlier report, a splicing mutation due to an insertion of
the 3′ region of a LINE1 in exon 44 of the dystrophin
gene was described in a DMD patient. This insertion
determined a larger exon and also its skipping, without
affecting the canonical splicing site. However, the inser-
tion mutation created a sequence with only one nucle-
otide (position4) different from the flanking consensus
sequence (Narita et al. 1993). As reported for other hu-
man and nonhuman genes, mutations either (a) abolish-
ing or reducing the efficiency of a canonical splicing site
or (b) creating a cryptic one may result in preferential
splicing regulation of alternative transcripts (Nelson and
Green 1990; Hahn et al. 1995; Sebillon et al. 1995).
In the family that we have described, the insertion of
this novel Alu-like element activates a cryptic acceptor
splicing site, already present in intron 11 of the dystro-
phin gene, without any mutation in either the canonical
splicing sites or the consensus sequences. We have dem-
onstrated that this mutation affects the splicing in a tis-
sue-specific way. To the best of our knowledge, this is
the first report in which such a mechanism has been
reported in a human genetic disease. However, the pos-
sibility that LINE, Alu, and other IRS might affect and
control the transcription of adjacent genes in various
species as well as in the human has been suggested in a
previous report (Favor and Morawetz 1992). Further-
more, in a few instances, although never in the human,
a tissue-specific induction of gene expression has been
found as a consequence of an IRS sequence’s insertion
(Adeniyi-Jones and Zasloff 1985; Tanda and Corces
1991). It seems most likely that this Alu-like sequence
might have played a direct role in regulation of the splic-
ing of the dystrophin gene in this family with XLDC. A
possible explanation is that the rearrangement that oc-
curred in intron 11 has brought the novel Alu-like se-
quence (and probably other flanking regulating regions)
close to the cryptic splice site, which is normally present
in the intron. This event activated this latter site, leading
to the alternative, nonefficient splicing in the cardiac-
muscle RNA as well as in the skeletal-muscle RNA, but
inhibited the normal canonical splicing in the cardiac-
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muscle RNA only. A related mechanism has been de-
scribed in maize, where, as a consequence of a THE
insertion/removal in the promoter region of the alcohol
dehydrogenase 1 gene, it causes variations in the tissue-
specific expression (Kloeckener-Gruissem and Freeling
1995). The role that the mobile elements actually play
in causing changes in humanDNA sequences and in gene
expression deserves further investigation.
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